These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7958470)

  • 21. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.
    Haglund K; Forman J; Kräusslich HG; Rose JK
    Virology; 2000 Mar; 268(1):112-21. PubMed ID: 10683333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuated Salmonella enterica serovar typhi live vector with inducible chromosomal expression of the T7 RNA polymerase and its evaluation with reporter genes.
    Santiago-Machuca AE; Ruiz-Pérez F; Delgado-Dominguez JS; Becker I; Isibasi A; González-Bonilla CR
    Plasmid; 2002 Mar; 47(2):108-19. PubMed ID: 11982332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
    Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
    J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
    Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
    Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine-induced HIV seropositivity: a problem on the rise.
    Van Braeckel E; Koutsoukos M; Bourguignon P; Clement F; McNally L; Leroux-Roels G
    J Clin Virol; 2011 Apr; 50(4):334-7. PubMed ID: 21300566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120.
    Gorse GJ; Patel GB; Mandava MD; Arbuckle JA; Doyle TM; Belshe RB;
    Vaccine; 2001 Feb; 19(13-14):1806-19. PubMed ID: 11166906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV.
    Vecino WH; Morin PM; Agha R; Jacobs WR; Fennelly GJ
    Immunol Lett; 2002 Jul; 82(3):197-204. PubMed ID: 12036602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.
    Gu R; Shampang A; Nashar T; Patil M; Fuller DH; Ramsingh AI
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and analysis of recombinant BCG vector systems.
    Fuerst TR; de la Cruz VF; Bansal GP; Stover CK
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1451-5. PubMed ID: 1466980
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunogenicity of chloroplast-derived HIV-1 p24 and a p24-Nef fusion protein following subcutaneous and oral administration in mice.
    Gonzalez-Rabade N; McGowan EG; Zhou F; McCabe MS; Bock R; Dix PJ; Gray JC; Ma JK
    Plant Biotechnol J; 2011 Aug; 9(6):629-38. PubMed ID: 21443546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses.
    Hone DM; Wu S; Powell RJ; Pascual DW; Van Cott J; McGhee J; Fouts TR; Tuskan RG; Lewis GK
    J Biotechnol; 1996 Jan; 44(1-3):203-7. PubMed ID: 8717405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinants.
    Gu R; Stagnar C; Zaichenko L; Ramsingh AI
    Vaccine; 2012 May; 30(24):3666-74. PubMed ID: 22464964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction and immunogenicity of Salmonella vaccine vector expressing HIV-1 antigen and MCP3.
    Bachtiar EW; Coloe PJ; Smooker PM
    Acta Microbiol Immunol Hung; 2009 Dec; 56(4):403-15. PubMed ID: 20038492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Silico Design and Immunologic Evaluation of HIV-1 p24-Nef Fusion Protein to Approach a Therapeutic Vaccine Candidate.
    Larijani MS; Sadat SM; Bolhassani A; Pouriayevali MH; Bahramali G; Ramezani A
    Curr HIV Res; 2018; 16(5):322-337. PubMed ID: 30605062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of oral CTL vaccine using a CTP-integrated Sabin 1 poliovirus-based vector system.
    Han SS; Lee J; Jung Y; Kang MH; Hong JH; Cha MS; Park YJ; Lee E; Yoon CH; Bae YS
    Vaccine; 2015 Sep; 33(38):4827-36. PubMed ID: 26241946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group.
    Gorse GJ; Yang EY; Belshe RB; Berman PW
    Clin Diagn Lab Immunol; 1996 Nov; 3(6):769-73. PubMed ID: 8914773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenovirus vaccine strains genetically engineered to express HIV-1 or HBV antigens for use as live recombinant vaccines.
    Hung PP; Chanda PK; Natuk RJ; Mason BB; Chengalvala M; Bhat BM; Molnar-Kimber KL; Dheer SK; Morin JE; Mizutani S
    Nat Immun Cell Growth Regul; 1990; 9(3):160-4. PubMed ID: 2196459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen.
    Shiraki K; Sato H; Yoshida Y; Yamamura JI; Tsurita M; Kurokawa M; Kageyama S
    J Med Virol; 2001 Jun; 64(2):89-95. PubMed ID: 11360239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles.
    Haffar OK; Smithgall MD; Moran PA; Travis BM; Zarling JM; Hu SL
    Virology; 1991 Aug; 183(2):487-95. PubMed ID: 1906660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.